Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) was the recipient of a large decline in short interest in October. As of October 30th, there was short interest totaling 28,547 shares, a decline of 95.9% from the October 15th total of 696,378 shares. Currently, 5.1% of the company’s stock are sold short. Based on an average daily volume of 63,445 shares, the short-interest ratio is currently 0.4 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on Capstone Therapeutics
Capstone Therapeutics Stock Performance
CAPS traded down $0.01 during mid-day trading on Tuesday, reaching $2.09. 6,375 shares of the stock were exchanged, compared to its average volume of 49,886. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.39. The company has a 50 day moving average price of $3.96 and a two-hundred day moving average price of $10.36. Capstone Therapeutics has a 1 year low of $1.85 and a 1 year high of $34.80.
About Capstone Therapeutics
Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.
See Also
- Five stocks we like better than Capstone Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
